Hypertension in pregnancy: evaluation of two beta blockers atenolol and labetalol

Publisher Website
Google Scholar
Abstract
There is a major controversy over the relative value of anti-hypertensive drugs in hypertension in pregnancy. Our purpose was to study two different beta-adrenolytic drugs, atenolol, a cardioselective beta blocker, and labetalol, an alpha-beta blocker. Fifty-six hypertensive (BP>140/90 mmHg). pregnant women were treated either with atenolol or labetalol. The patients were divided into two subgroups for which there were no statistical differences with regard to age, number of previous pregnancies, initial level of blood pressure and uricemia, proteinuric pre-eclampsia, beginning of therapeutic trial and delivery. The average daily dosage was 144·6±47·8 mg day−1 with atenolol and 614±47·8 mg day−1 with labetalol. This study shows: It is concluded that atenolol and labetalol are safe and they are usually effective in the control of the hypertension complicating pregnancy. But labetalol appears to he better able to prevent the appearance of fetal growth retardation.

This publication has 0 references indexed in Scilit: